Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis
Authors:
Top Cited Papers
Open Access
- 19 August 2022
- journal article
- review article
- Published by Elsevier in European Urology
- Vol. 82 (6) , 584-598
Abstract
No abstract availableKeywords
Funding Information
- European Association of Urology
This publication has 39 references indexed in Scilit:
- Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 TrialEuropean Urology, 2016
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialThe Lancet, 2016
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerNew England Journal of Medicine, 2015
- Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2013
- Androgen Receptor on the Move: Boarding the Microtubule Expressway to the NucleusCancer Research, 2012
- Molecular States Underlying Androgen Receptor Activation: A Framework for Therapeutics Targeting Androgen Signaling in Prostate CancerJournal of Clinical Oncology, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: A tutorialBMC Medical Research Methodology, 2010
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLOS Medicine, 2009
- Measuring inconsistency in meta-analysesBMJ, 2003